• Loading stock data...
Est. 2004

LEVERAGE OUR MASSIVE INVESTOR AUDIENCE!

Stock Investors · Accredited Investors · Hedge Fund Investors

Learn More

Sunday 04/22/2018
SMALL CAP MARKET NEWS

We release small market news updates daily, 5 times a week! Always check back to get the inside scoop on what going on.


LEVERAGE OUR MASSIVE INVESTOR AUDIENCE!

Stock Investors · Accredited Investors · Hedge Fund Investors

Learn More

AIDS

  • 1:55 PM

    ORLANDO, Fla., Sept. 06, 2017, IMUN, (GLOBE NEWSWIRE) — Immune Therapeutics, Inc. (OTCQB:IMUN), a specialty pharmaceutical company focused on developing and commercializing Lodonal™, its patented, affordable, non-toxic therapy for the management of cancer, HIV, autoimmune diseases and other inflammatory conditions, today announced that it has entered into an exclusive agreement with Kenya-based Omaera Pharmaceuticals, Ltd. for the sale and distribution of Lodonal™, valued at a minimum of $31 million in revenues over three years. A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/d02d7135-cf47-471f-9fa0-17fa3e9728a7. Under the

    Read more
  • 2:35 PM

    ORLANDO, Fla., May 19, 2016, IMUN, /PRNewswire/ — Immune Therapeutics, Inc. (OTCQB: IMUN ), a clinical-stage biotech company providing immunotherapy solutions for the treatment of infectious and non-infectious diseases, such as HIV/AIDS and cancer, with a focus on emerging nations, today announced its attendance at the 69th World Health Assembly ( ” WHA ” ) in Geneva, Switzerland to promote LodonalTM. The WHA is the decision-making body of the World Health Organization (“WHO”). It is attended by delegations from all WHO member

    Read more
  • 2:26 PM

    ORLANDO, Fla., April 27, 2016, IMUN, (GLOBE NEWSWIRE) — Immune Therapeutics, Inc. (OTCQB:IMUN) (the “Company”), a clinical-stage biotech company providing immunotherapy solutions for the treatment of autoimmune disease and cancer with a focus on emerging nations, today announced that Nigeria’s National Agency for Food and Drug Administration and Control (NAFDAC) has approved its patented Lodonal as an over the counter, non-toxic adjunct therapy in the treatment of HIV/AIDS and immune system regulator. The receipt of NAFDAC’s approval will enable the

    Read more
  • Immune Therapeutics
    2:10 PM

    ORLANDO Fla., April 11, 2016, IMUN, /PRNewswire/ — Immune Therapeutics, Inc. (OTCQB: IMUN); a clinical-stage international biotechnology company providing immunotherapy solutions for the treatment of diseases, autoimmune diseases, and cancer, announced today it is providing shareholders with a status update of Immune Therapeutics, Inc.’s (IMUN) drug development program in China with long-term partner Hubei Qianjiang Pharmaceutical Co. Ltd (Qianjiang). The Economist Intelligence Unit (EIU) projects $166 billion in drug sales in China by 2017, providing a recognized market to  further growth.

    Read more
  • Immune Therapeutics
    4:52 PM

    ORLANDO, Fla., March 3, 2016, IMUN, /PRNewswire/ — Immune Therapeutics, Inc. (OTC:BB IMUN), a specialty pharmaceutical company involved in the manufacture, commercialization, distribution and marketing of novel, patented therapies to combat chronic, life-threatening diseases through the activation and modulation of the body’s immune system, today announced the appointment of two new members to its Board of Directors: Clifford A. Selsky, Ph.D., MD, and Paul Akin. “Paul Akin and Dr. Selsky ‘s breadth of knowledge and experience will provide invaluable insight to

    Read more
Public Wire Banner